Exasol H1 revenue falls on lower non-recurring sales
Exasol H1 revenue falls on lower non-recurring sales
Overview
Germany database technology firm's preliminary H1 revenue fell yr/yr on lower non-recurring sales
ARR was nearly flat at EUR 37.9 mln as of June 30, 2026
Company added eleven new customers but saw weaker expansion with existing clients
Outlook
Exasol expects 2026 ARR to change by between -2% and +2%
Company forecasts 2026 revenue to decline in the upper-single-digit percentage range
Exasol projects 2026 EBITDA between EUR 3.0 mln and EUR 3.5 mln
Result Drivers
LOWER NON-RECURRING SALES - Revenue decline was mainly due to a sharp drop in non-recurring hardware and service revenue
WEAK EXISTING CUSTOMER EXPANSION - Expansion of existing customer relationships was below expectations due to reduced willingness to invest in new on-premises infrastructures and a delayed sales rollout with a strategic cooperation partner
NEW CUSTOMER MOMENTUM - Addition of eleven new customers driven by focus on data sovereignty and agentic AI workloads
LOWER ARR CHURN - Contract cancellations and adjustments decreased, with rolling ARR churn rate dropping to 10% from 24% at end-2025
Company press release: ID:nEQ5fZqzma
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Revenue |
| EUR 19 mln |
|
H1 ARR |
| EUR 37.90 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the business support services peer group is "buy."
Wall Street's median 12-month price target for Exasol AG is €4.25, about 117.9% above its August 18 closing price of €1.95
The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 19 three months ago
Reuters Recommended Reads
Aug 18 - Germany's YOC H1 revenue rises on international business growth
Aug 18 - Germany's JDC Group Q2 revenue up 17% on Advisortech unit strength
Aug 18 - Germany's Hoenle nine-month revenue dips on curing unit weakness
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)